company background image
NGM logo

NGM Biopharmaceuticals NasdaqGS:NGM Stock Report

Last Price

US$1.61

Market Cap

US$133.2m

7D

9.5%

1Y

-65.9%

Updated

21 Feb, 2024

Data

Company Financials +

NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Stock Report

Market Cap: US$133.2m

NGM Stock Overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer.

NGM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NGM Biopharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NGM Biopharmaceuticals
Historical stock prices
Current Share PriceUS$1.61
52 Week HighUS$4.84
52 Week LowUS$0.60
Beta1.27
1 Month Change25.78%
3 Month Change128.37%
1 Year Change-65.89%
3 Year Change-94.35%
5 Year Changen/a
Change since IPO-89.05%

Recent News & Updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09
Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17
NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Mar 02
We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year

Jan 26
Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year

NGM Bio gives update on 2021 plans and data timeline

Jan 12

NGM Bio prices $125M share offering

Jan 06

NGM Biopharmaceuticals proposes $100M public offering

Jan 04

Here's What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Shareholder Ownership Structure Looks Like

Dec 22
Here's What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Shareholder Ownership Structure Looks Like

Have Insiders Been Selling NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Shares?

Nov 26
Have Insiders Been Selling NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Shares?

NGM Biopharmaceuticals EPS misses by $0.04, beats on revenue

Nov 12

Shareholder Returns

NGMUS PharmaceuticalsUS Market
7D9.5%0.8%-0.5%
1Y-65.9%20.2%22.3%

Price Volatility

Is NGM's price volatile compared to industry and market?
NGM volatility
NGM Average Weekly Movement17.1%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

About the Company

FoundedEmployeesCEOWebsite
2007239David Woodhousehttps://www.ngmbio.com

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company’s product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 which is in phase I clinical trial for the treatment of advanced solid tumors.

NGM Biopharmaceuticals, Inc. Fundamentals Summary

How do NGM Biopharmaceuticals's earnings and revenue compare to its market cap?
NGM fundamental statistics
Market capUS$133.17m
Earnings (TTM)-US$151.14m
Revenue (TTM)US$22.43m

5.9x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NGM income statement (TTM)
RevenueUS$22.43m
Cost of RevenueUS$139.06m
Gross Profit-US$116.63m
Other ExpensesUS$34.51m
Earnings-US$151.14m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.83
Gross Margin-519.89%
Net Profit Margin-673.75%
Debt/Equity Ratio0%

How did NGM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.